NAFDAC raises alarm over new fake cancer drug

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert warning Nigerians about the circulation of an unauthorized and unregistered cancer drug, Darzalex (Daratumumab) 1800mg/15ml vial SC Injection, in the country.

In Public Alert No. 031/2025, released on October 15, the agency said the product was not registered in Nigeria and did not pass through authorized Johnson & Johnson distributors.

According to NAFDAC, an internal investigation by Johnson & Johnson discovered two different packaging designs of the drug, one made for the Indian market and another for the Arab market. The India batch, identified as Lot No: PKS1F01, carries an expiry date of October 2026, while the lot number for the Arab version could not be confirmed.

NAFDAC emphasized that Darzalex, a cold-chain product used in the treatment of multiple myeloma (a blood cancer affecting plasma cells), is not registered for sale or distribution in Nigeria.

The agency warned that buying medicines from unauthorized or unregistered sources could expose patients to counterfeit, tampered, stolen, or substandard products that pose serious health risks.

To curb distribution, NAFDAC has directed its zonal directors and state coordinators to conduct surveillance and mop up the fake product from the market.

Healthcare professionals, importers, distributors, and retailers were also urged to remain vigilant and ensure that all medical products are sourced only from authorized and licensed suppliers.

“All medical products must be obtained from approved sources. The authenticity and physical condition of every item should be verified before use,” NAFDAC stated.

The agency urged the public to immediately report any suspicion of the fake Darzalex injection to the nearest NAFDAC office or through its official complaint channels.